|
Haryana DC launches new digital monitoring system to track high-risk solvents to prevent fatal contamination
|
|
Peethaambaran Kunnathoor, Chennai
October 28 , 2025
|
|
|
The Haryana Food and Drugs Administration (FDA) has enforced a massive regulatory overhaul and launched a new digital monitoring system to track high-risk pharmaceutical solvents.
This decisive action was directly precipitated by a public alert concerning the fatal contamination of cough syrups with industrial chemicals. The move, mandated by the Central Drugs Standard Control Organisation (CDSCO), aims to achieve zero tolerance for toxic contamination, specifically from chemicals like diethylene glycol (DEG) and ethylene glycol (EG).
According to Lalit Kumar Goel, the state drug controller of Haryana, based on official communication received from the FDA in Madhya Pradesh and Gujarat, the public alert confirmed that certain drug formulations were found containing DEG impurity above permissible limits and were declared adulterated and Not of Standard Quality (NSQ). This finding, which specifically implicated cough syrups like Respifresh TR and Relife, prompted the FDA in Haryana to alert all drug inspectors. They were instructed to maintain strict vigil, draw samples, and seize the remaining stocks of these contaminated medicines. Goel also warned solvent manufacturers through the Haryana Pharmaceutical Manufacturers Association against the use of any contaminated raw materials leading to DEG adulteration, emphasizing the need to keep the pharmaceutical supply chain secure, he told Pharmabiz in a telephonic talk.
Following the CDSCO’s directive on October 22, 2025, Goel issued a memo instructing solvent manufacturers to register on the Online National Drug Licensing System (ONDLS) portal.
“The focus of the new digital watch is a list of high-risk solvents essential for liquid oral medicines, including propylene glycol, glycerin, sorbitol, and various polyethylene glycols. Under the new rules, manufacturers are required to upload comprehensive details for every batch produced. This includes the total quantity, the official Certificate of Analysis (CoA) to verify purity, and the specific details of every vendor or pharmaceutical company purchasing the material”, he said.
In a show of cooperation, the Haryana Pharmaceutical Manufacturers Association (HPMA) has publicly supported the transparency drive. HPMA officials confirmed that none of their current member units are engaged in the manufacturing of the high-risk solvents now under digital surveillance. They also affirmed their readiness to share information immediately if any member unit receives such compounds, ensuring full compliance and accountability within the state’s industry.
This mandatory digital registration on the ONDLS portal ensures real-time oversight of critical ingredients, making Haryana a leader in enforcing stricter quality norms post-contamination incidents. By mandating the licensing and batch-level tracking of solvents, the state government is working to secure the integrity of every medicine batch, moving towards a contaminants-free drug ecosystem, it is learnt.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|